Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 15;10:15086. doi: 10.1038/s41598-020-72155-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PARP activity is not required for the repression of p57 and myogenin induction. Left panels: western blot analyses of PAR levels in C2.7 differentiating in the presence of either Veliparib (upper) or Olaparib (lower). Protein samples were prepared from cells proliferating in growth medium (GM) and from cells shifted to differentiation in medium (DM), in the presence of 1 µM Veliparib, 1 µM Olaparib or the control vehicle DMSO (vehicle) and kept for 24 and 48 h. PARylated proteins were detected with the anti-PAR antibody. ERK1 was used as an invariant control. One representative of three independent experiments is shown. Full length blots are presented in Fig. S11. Right panels: RT-qPCR analysis of p57 and myogenin (MyoG) expression in C2.7 cells differentiated in the presence of Veliparib (upper right) or Olaparib (lower right), as described for western blot analyses. Expression levels, relative to those of Tbp RNA and expressed as fold change respect to the control at 24 h represent the mean ± SEM of three independent experiments. Statistical significance: p-value < 0.05 (*) and < 0.01 (**); ns stands for not significant.